BiotechTube
Home/Nurix Therapeutics/Katherine V. St. John
KV

Katherine V. St. John

Director

Nurix Therapeutics

Therapeutic Areas

OncologyImmunology

Nurix Therapeutics Pipeline

DrugIndicationPhase
NX-5948Relapsed/Refractory B-cell Malignancies (CLL, NHL)Phase 1b
NX-2127Relapsed/Refractory B-cell MalignanciesPhase 1a/1b
NX-1607Advanced Solid TumorsPhase 1a
NX-0479 (GS-6791)Oncology (undisclosed)Preclinical
DeTIL-0255Solid TumorsPreclinical

Leadership Team at Nurix Therapeutics

AT
Arthur T. Sands
President, Chief Executive Officer, and Director
GM
Gwenn M. Hansen
Chief Scientific Officer
JR
John R. (Rich) K. Hsu
Chief Medical Officer
CO
Christine O. Miller
Chief Legal Officer and Corporate Secretary
SW
Stephanie Wong
Chief Financial Officer
NF
Nathalie Franchimont
Chief Development Officer
GG
Gary G. Glick
Founder and Director
DD
David D. Chang
Director
BC
Brian C. Cunningham
Director
LK
Laurie Keating
Director
View full Nurix Therapeutics profile